Showing results (3411-3420 of 3,662) with videos related to

Sort By:
Pageof 367
Breast (Edinburgh, Scotland)|November 13, 2016
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysisMarta Bonotto, Lorenzo Gerratana, Massimo Di Maio, et al.
Breast (Edinburgh, Scotland)|November 13, 2016
Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test resultAnne Brédart, Jean-Luc Kop, Antoine De Pauw, et al.
Breast (Edinburgh, Scotland)|November 18, 2016
Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancersK Ashok Reddy, P Uday Kumar, M Srinivasulu, et al.
Breast (Edinburgh, Scotland)|November 5, 2016
Associated factors with psychological distress in Moroccan breast cancer patients: A cross-sectional studySoufiane Berhili, Selma Kadiri, Amal Bouziane, et al.
Breast (Edinburgh, Scotland)|November 5, 2016
Intraoperative assessment of sentinel lymph node by one-step nucleic acid amplification in breast cancer patients after neoadjuvant treatment reduces the need for a second surgery for axillary lymph node dissectionMartin Espinosa-Bravo, Joaquin Navarro-Cecilia, Manuel Ramos Boyero, et al.
Breast (Edinburgh, Scotland)|November 5, 2016
Improved survival in metastatic breast cancer 1985-2016Marie Sundquist, Lars Brudin, Göran Tejler
Breast (Edinburgh, Scotland)|November 7, 2016
Severe fatigue after treatment of ductal carcinoma in situ: A comparison with age-matched breast cancer survivors and healthy controlsH J G Abrahams, L Smits, M de Lugt, et al.
Breast (Edinburgh, Scotland)|December 4, 2016
Reducing implant loss rates in immediate breast reconstructionsL Darragh, A Robb, C M Hardie, et al.
Breast (Edinburgh, Scotland)|February 16, 2019
Peptide vaccines in early breast cancerCarmen Criscitiello, Giulia Viale, Giuseppe Curigliano
Breast (Edinburgh, Scotland)|March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyA Mavratzas, S Baek, B Gerber, et al.
Pageof 367